Fitch Ratings: The stable outlook means that no downgrade is expected in the next one to two years, and the dollar’s status as a reserve currency remains a key factor despite recent dollar exchange rate fluctuations.

Important News 1. Tax authorities will further advance tax system reform in 2026. 2. The total assets of central enterprises exceeded 95 trillion yuan. 3. China Merchants Bank will raise the minimum subscription amount for gold accounts to 1,200 yuan. 4. Several leading quantitative trading institutions responded that the rumor of "changes in quantitative stock trading rules" is false. 5. National Energy Administration: As of the end of 2025, the cumulative installed power generation capacity nationwide reached 3.89 billion kilowatts, a year-on-year increase of 16.1%. 6. National Medical Products Administration: Two medical device industry standards, including "Paradigm Design and Application Specifications for Motor Function Reconstruction of Medical Devices Using Brain-Computer Interface Technology," have been approved. 7. Shenzhen Luohu District issued a statement regarding rumors of payment difficulties on a gold pre-order platform in Shuibei. Individual Stock News 1. Data on main capital flow shows that China Aluminum saw the largest net inflow of main capital at 1.909 billion yuan, followed by N Hengyunchang, Northern Rare Earth, Wangsu Science & Technology, and Tianfu Communication; BlueFocus saw the largest net outflow of main capital at 2.466 billion yuan, followed by Sungrow Power, Kweichow Moutai, CATL, and Aerospace Electronics. 2. Zhongwei New Materials: The rise in LME nickel prices has a positive impact on the company's operating profit. 3. Luoyang Molybdenum's cobalt products from the Democratic Republic of Congo have been exported. 4. Guotai Haitong and Guomao Holdings have reached a strategic cooperation agreement. 5. Boying Special Welding: Eight production lines are under construction at its Vietnam base, expected to be put into operation successively in the second and fourth quarters. 6. Hengrui Medicine's oral small molecule GLP-1R agonist has been approved for Phase III clinical trials for hypertension combined with overweight or obesity.

The CEO of Trafigura India, a global commodities trading giant, said that India's oil demand will approach 9 million barrels per day by 2050.